Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Diffuse Large B Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1034
)
Mantle Cell Lymphoma (124
)
T Cell Non-Hodgkin Lymphoma (117
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1034
)
Mantle Cell Lymphoma (124
)
T Cell Non-Hodgkin Lymphoma (117
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(374)
News
Trials
Search handles
@ARampotas
@AaronGoodman33
@AnnaSureda5
@AshAlizadeh
@ChenyuLinMD
@CwynKate
@DanilovLab
@DrAEvens
@DrBonillaOnc
@DrChoueiri
@DrChrisPFox
@DrJFriedberg
@DrLizBrem
@DrMCanales
@DrMiguelPerales
@DrRaulCordoba
@Dr_Daniel_Molin
@Fer_martinmoro
@FunchainMD
@GlopesMd
@HadidiSamer
@HayderSaeed_MD
@HenrychihangFu1
@HiraseMD
@JiaJennyLiu
@JohnPLeonardMD
@Kwudhikarn
@LeonidasPlatan1
@Lymphoma_Doc
@Lymphoma_MD
@MDonatoBMT
@MediHumdani
@MichaelDJain
@Mike_Oertel_MD
@PLMcCarthyMD
@Prasshmehta
@RabiHannaMD
@RahulBanerjeeMD
@RemyDulery
@RenoHemonc
@Rfonsi1
@SCTNB
@SuyogCancer
@Transplant_Doc
@VincentRK
@VivekSubbiah
@albertomussetti
@amarkelkar
@bagalbp
@chadinabhan
@chanyooncheah
@davidhenrymd
@dgermain21
@doctorpemm
@drjgauthier
@drkomanduri
@fabianeac
@gary_lyman
@gloria_iacoboni
@graham74GC
@hematologo
@ixazebe
@lingarajnayak
@majorajay
@matthew_mei
@michaelwangmd
@mike_dickinson1
@mtmdphd
@smbenlazar
@syed_abutalibmd
@timfenske
@tobyeyre82
@weldeiry
@ymori117
Search handles
@ARampotas
@AaronGoodman33
@AnnaSureda5
@AshAlizadeh
@ChenyuLinMD
@CwynKate
@DanilovLab
@DrAEvens
@DrBonillaOnc
@DrChoueiri
@DrChrisPFox
@DrJFriedberg
@DrLizBrem
@DrMCanales
@DrMiguelPerales
@DrRaulCordoba
@Dr_Daniel_Molin
@Fer_martinmoro
@FunchainMD
@GlopesMd
@HadidiSamer
@HayderSaeed_MD
@HenrychihangFu1
@HiraseMD
@JiaJennyLiu
@JohnPLeonardMD
@Kwudhikarn
@LeonidasPlatan1
@Lymphoma_Doc
@Lymphoma_MD
@MDonatoBMT
@MediHumdani
@MichaelDJain
@Mike_Oertel_MD
@PLMcCarthyMD
@Prasshmehta
@RabiHannaMD
@RahulBanerjeeMD
@RemyDulery
@RenoHemonc
@Rfonsi1
@SCTNB
@SuyogCancer
@Transplant_Doc
@VincentRK
@VivekSubbiah
@albertomussetti
@amarkelkar
@bagalbp
@chadinabhan
@chanyooncheah
@davidhenrymd
@dgermain21
@doctorpemm
@drjgauthier
@drkomanduri
@fabianeac
@gary_lyman
@gloria_iacoboni
@graham74GC
@hematologo
@ixazebe
@lingarajnayak
@majorajay
@matthew_mei
@michaelwangmd
@mike_dickinson1
@mtmdphd
@smbenlazar
@syed_abutalibmd
@timfenske
@tobyeyre82
@weldeiry
@ymori117
Filter by
Latest
9ms
New manuscript published in @BloodAdvances validating the new "Severe4" comorbidity index to predict post-CAR-T outcomes in DLBCL, with our @CULymphoma faculty Drs. @StevenBairMD and @mana1981 contributing. #lymsm #celltherapy cc @DanilovLab https://t.co/yi58TtfUz5 (@CULymphoma)
9 months ago
9ms
A discussion with Matthew Matasar, MD, MS, on using loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell #lymphoma. #DLBCL #lymsm | @DrMatasar @RutgersCancer https://t.co/LKM8ZtGFIq (@TargetedOnc)
9 months ago
Clinical
|
lenalidomide • Zynlonta (loncastuximab tesirine-lpyl) • Monjuvi (tafasitamab-cxix)
9ms
Suffering "Diffuse large B-cell lymphoma" ZEBA TAHSIN 16Y my daughter. advice to survive properly (@MdZahid1974)
9 months ago
9ms
But sir you will be astonished that in a country like Pakistan , people do not have access to Rituximab even in DLBCL...herceptin/Perjecta in Breast cancer,Others talking of polatuzuma,even for PFS benefits only....Do these patients have no rights to access to quality drugs? (@DrManzoorKhan1)
9 months ago
Clinical
|
Herceptin (trastuzumab) • Rituxan (rituximab)
9ms
War auch meine Einschätzung. Verlauf eher nicht wie DLBCL. Aber es ist eine Zumutung jemanden 6 Monate mit den Gedanken um ein wahrscheinliches Malignom einfach so rumlaufen zu lassen. (@omakaffeekanne)
9 months ago
10ms
Please check & study below reports for my disease, CANCER DLBCL NHL" Suffering...want survive (@MdZahid1974)
10 months ago
10ms
CANCER DLBCL NHL, 8 months suffering. (@MdZahid1974)
10 months ago
10ms
Looking forward to catching up on podcasts this weekend? Don't miss the latest episode of The HemOnc Pulse, which features @GregNowakowski of @MayoClinic discussing the latest developments in DLBCL with host @chadinabhan. 🔊: https://t.co/yw43xYgZzR (@Blood_Cancers)
10 months ago
10ms
CANCER DLBCL NHL, suffering 8 months, (@MdZahid1974)
10 months ago
10ms
To better understand diffuse large B-cell lymphoma, MyLymphomaTeam spoke with @timfenske, a hematologist and medical oncologist who specializes in lymphoma. Read more:https://t.co/203m0fv92w (@MyLymphomaTeam)
10 months ago
10ms
@WomenInLymphoma @lymphomaoz @DrElizaHawkes @SehnLaurie @SoniSmithMD @AllisonBarra1 #lymsm #lymphoma #DLBCL (@WomenInLymphoma)
10 months ago
10ms
Register for @OncLive's State of the Science Summit: Leukemia/Lymphoma Updates in Myelofibrosis w/ program chair @JeannePalmerMD. Topics include: ➡BTK Inhibitors in MCL ➡Bispecific Antibodies in DLBCL ➡CAR T-Cell Therapy ➡Updates in CLL ➡Live Q&A https://t.co/CdVQnUkgVP (@MayoCancerCare)
10 months ago
CAR T-Cell Therapy
10ms
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma | NEJM https://t.co/Qa0JdrrrmH #bmtsm #lymsm @Lymphoma_Doc (@Transplant_Doc)
10 months ago
Yescarta (axicabtagene ciloleucel)
10ms
Check out our interview w/ @pattymondello of @MayoClinic, who shares some insights into a study investigating the impact of magnesium levels on the outcomes of patients with LBCL treated w/ axi-cel 👇: https://t.co/LpLavUru83 @icmlugano #17ICML #LymSM #DLBCL #CART #ImmunoOnc (@VJHemOnc)
10 months ago
Clinical • Interview
|
Yescarta (axicabtagene ciloleucel)
10ms
#SOHO2023 speaker @GregNowakowski of @MayoClinic discusses revolutionary treatments in DLBCL, data from the L-MIND study, and more with host @chadinabhan on this week's HemOnc Pulse. (@SocietyofHemOnc)
10 months ago
10ms
🔊OUT NOW: The latest episode of The HemOnc Pulse features @GregNowakowski of @MayoClinic discussing revolutionary treatments in DLBCL, data from the L-MIND study, and more with host @chadinabhan. Listen: https://t.co/bohKhtN1Lr @SocietyofHemOnc (@Blood_Cancers)
10 months ago
10ms
👉🏽7/10 invited manuscript by @WomenInLymphoma for #HematologicalOncology @icmlugano "Diffuse large B-cell lymphoma" 🔗https://t.co/1Ox6UZzXyk #lymsm #lymphoma #DLBCL @lymphomaOz @DrElizaHawkes @SehnLaurie @SoniSmithMD @AllisonBarra1 (@WomenInLymphoma)
10 months ago
10ms
New episode of The HemOnc Pulse coming Thursday, 7/13. @GregNowakowski chats with host @chadinabhan on the revolutionary treatments in DLBCL and more. @SocietyofHemOnc @SagarLonialMD (@Blood_Cancers)
10 months ago
10ms
Very grateful to @ligordon and Adam Yuh Lin for their Commentary on our JCI article. #Lymphoma #DLBCL #Immunotherapy https://t.co/mBVxv5Z1V4 (@RamsayLab)
10 months ago
10ms
Suffering CANCER DLBCL NHL, (@MdZahid1974)
10 months ago
10ms
Very challenging situation, my views- 1. Time is essence- act at the earliest 2. Poor PS alone- not a contraindication if due to disease and then best way to improve PS is treat it 3. Worst prognosis amongst extranodal DLBCL- inform family and involve in decision making (@bagalbp)
10 months ago
10ms
At #17ICML, @Fer_martinmoro spoke to us about a retrospective analysis which compared the aaIPI, LAB-PI, NCCN-IPI and GELTAMO-IPI prognostic scores. Watch his interview here: 👉 https://t.co/iaikVCeZmp 👈 @icmlugano #LymSM #DLBCL #HemOnc (@VJHemOnc)
10 months ago
Retrospective data • Interview
10ms
#Molecular determinants of #ClinicalOutcomes in a real-world diffuse large B-cell #lymphoma population A nice editorial! 👉https://t.co/kjMih8HEJa @BloodJournal @WaleedAlduaij #DLBCL (@davidhenrymd)
10 months ago
Clinical • Clinical data • Real-world evidence • Real-world
10ms
Expert panelists open a discussion on DLBCL by reflecting on diagnostic strategies and the frontline treatment armamentarium. @drjoannarhodes1 @Lymphoma_Doc @lymphomaphilia @YucaiWangMD @HayderSaeed_MD #lymsm https://t.co/hthHaJ3c3u (@OncLive)
10 months ago
10ms
What are the recent developments in treating diffuse large B cell lymphoma? And what novel therapies are on the horizon? Our Dr. Loretta Nastoupil shares her insights in this interview: https://t.co/K2vpfFyZjs @medpagetoday @LNastoupilMD #lymphoma #EndCancer (@MDAndersonNews)
10 months ago
Interview
10ms
Successful Chimeric antigen receptor T-cell therapy in an ESKD patient for the treatment of relapsed DLBCL. @jaykoyner @uofcneph @UCCancerCenter https://t.co/IH11eTsuFw (@Nephr0s)
10 months ago
Clinical • CAR T-Cell Therapy
10ms
Matthew Matasar, MD, MS, on data supporting the safety and efficacy of loncastuximab tesirine in patients with #DLBCL. #lymsm | @RutgersCancer @DrMatasar https://t.co/vhuI7XlGcW (@TargetedOnc)
10 months ago
Clinical
|
Zynlonta (loncastuximab tesirine-lpyl)
10ms
Want to learn more about the MOA of BTK degraders & the activity of NX-2127 in patients with R/R B-cell malignancies? Alexey Danilov (@DanilovLab; @cityofhope) shares some insights: 👉 https://t.co/9I55kTZqsn @icmlugano #17ICML #LymSM #LeuSM #CLLsm #DLBCL #ImmunoOnc (@VJHemOnc)
10 months ago
Clinical
|
NX-2127
10ms
suffering cancer DLBCL NHL, 08 month, received 8 cycles chemo already, want to live without CHEMO & CANCER,,thanks, (@MdZahid1974)
10 months ago
10ms
Dear hem-onc fellas, based on the #17ICML Lugano impressions, what would you choose 🤔 In RR DLBCL, 12mo after 6th R-CHOP, 70 yo male, KS III, no EN, no bulk, ECOG 1, LVEF 40, otherwise healthy Thanks! (@vit_prochazka)
10 months ago
Clinical
|
Rituxan (rituximab)
10ms
At #ASCO23, Dr. Jason Westin (@Lymphoma_Doc) of @MDAndersonNews presented primary OS results of the #ZUMA7 trial of #axicabtagene ciloleucel for relapsed/refractory #DLBCL. Listen as he shares more about the results in this podcast! https://t.co/sqe9iUN5Lb #axicel #lymphoma (@OncData)
10 months ago
Yescarta (axicabtagene ciloleucel)
10ms
Elegant work by Drs. Laura Hilton and David Scott @JCO_ASCO These results emphasize the importance of repeat biopsy and molecular analysis of relapsed DLBCL, and further our understanding of malignant B-cell evolutionary dynamics. A great contribution. https://t.co/rb2ngKH1MG (@DrJFriedberg)
10 months ago
Biopsy
10ms
79% of complete responders are still in remission 15 months out while on Epco in RR DLBCL #lymsm #17icml https://t.co/tJijrzVcla (@HayderSaeed_MD)
10 months ago
Clinical
10ms
Outside HL and interim PET, we should consider the PPV limitations of EOT PET not only in HL, but also in PMBL (eg 25% XRT in Davies study), and 1L DLBCL (eg 25% DS4/5 as basis for eligibility for 2L CART). I would guess those interventions to cost $ billions in each year. (@AshAlizadeh)
10 months ago
Pricing
10ms
ICML highlights. EOT MRD predicts outcome in DLBCL @ALLGtrials @AshAlizadeh @mhertzberg10 @RoschewskiMD (@OpatStephen)
10 months ago
10ms
CDK9 is an important target in NHL. In heavily-pretreated DLBCL pts including many post CAR-T, ORR/CR 50%/20% and some are durable. Excited to share clinical data on the molecule our lab and Australian colleagues helped advance into trials #ICML17 @JohnstoneRicky @DrAnasYounes (@DanilovLab)
10 months ago
Clinical data
|
CDK9 (Cyclin Dependent Kinase 9)
10ms
9% infection related mortality in the FL and DLBCL cohorts with #odronextamab #ICML2023 (@tobyeyre82)
10 months ago
odronextamab (REGN1979)
10ms
Interim results from DALY II of zamto-cel presented by @MattUlricksonMD with dual CD19/CD20 CAR for DLBCL in the 3L+ setting; 22 pts treated with promising 80+% ORR and CR rate in 50s although very early data #17ICML; also no prior CAR exposure among pts which is a remaining need (@AlexandraRojek)
10 months ago
Clinical
|
CD20 (Membrane Spanning 4-Domains A1)
10ms
suffering CANCER DLBCL NHL, zeba tahsin 16Y, (@MdZahid1974)
10 months ago
10ms
ELM-2 interim results #17ICML: -140 pts with R/R DLBCL (2+ LOT) - ORR 49%, 48% if CAR exposed - mPFS only 4.4 mos, mDOR 10 mod - 5 Gr5 AEs (mostly infections), less high grade CRS with step up dosing It's the BITE era for #lymsm! (@majorajay)
10 months ago
Clinical
10ms
#17ICML . Catherine Thieblemont. Epcoritamab in R/R DLBCL. EPCORE NHL-1. Median FU 20m. CR LBCL,39; DLBCL,40%. DoR 68%, 20.8 m @GuiperiniMD @GELL01433166 (@hematologo)
10 months ago
Epkinly (epcoritamab-bysp)
10ms
CONGRESS|#17ICML Martin Hutchings(@DocHutchings),@Rigshospitalet presents the updated data on glofitamab plus polatuzumab vedotin in R/R DLBCL which led to high & durable responses & a manageable safety profile. -Best responses: ORR of 78% & CR: 56% -Mostly low-grade CRS #lymsm (@lymphomahub)
10 months ago
Clinical
|
Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login